z-logo
Premium
Immune responses against tumour‐associated antigen‐derived cytotoxic T lymphocyte epitopes in cholangiocarcinoma patients
Author(s) -
Kida Akihiko,
Mizukoshi Eishiro,
Tamai Toshikatsu,
Terashima Takeshi,
Kitahara Masaaki,
Arai Kuniaki,
Yamashita Tatsuya,
Fushimi Kazumi,
Honda Masao,
Kaneko Shuichi
Publication year - 2018
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.13885
Subject(s) - elispot , epitope , cytotoxic t cell , antigen , ctl* , immunology , immunotherapy , immune system , carcinoembryonic antigen , medicine , tumor antigen , t cell , cancer research , biology , cd8 , cancer , biochemistry , in vitro
Background & Aims Immunotherapy is a promising treatment option for cholangiocarcinoma. We compared cytotoxic T lymphocyte ( CTL ) responses against several tumour‐associated antigen ( TAA )‐derived epitopes in cholangiocarcinoma patients to identify candidate epitopes for immunotherapy. Methods Twenty‐six TAA s were selected, and the expression of TAA s in 6 cholangiocarcinoma cell lines and 9 specimens were measured using real‐time polymerase chain reaction ( PCR ). CTL responses against 38 TAA ‐derived epitopes were measured using samples from 26 cholangiocarcinoma patients by interferon‐γ enzyme linked immunospot ( ELISPOT )‐assay. Results Most TAA s were expressed in cholangiocarcinoma cell lines and specimens in PCR . Epitopes that stimulated a specific immune response were defined as those that elicited a CTL response in more than 3 patients and little response in healthy volunteers, as measured by ELISPOT ‐assay. Based on these criteria, there were 18 epitopes that stimulated specific immune responses: squamous cell carcinoma antigen recognized by T cells ( SART )1 690 , P53 161 , multidrug resistance‐associated protein ( MRP )3 503 , Survivin2B 80 , melanoma‐associated antigen ( MAGE )‐A4 143 , receptor tyrosine kinase ErbB‐2/neu (Her2/neu) 63 , Wilms tumour ( WT 1) 235 , WT 1 417 , β‐catenin 29 , carcinoembryonic antigen ( CEA ) 268 , CEA 652 , epithelial cell adhesion molecule (Ep CAM ) 173 , enhancer of zeste homolog ( EZH )2 291 , mucin 5 AC ( MUC 5 AC ) 716 , glypican‐3 ( GPC 3) 298 and kinesin family member 20A ( KIF 20A) 66 . Furthermore, the absolute number of lymphocytes in peripheral blood was significantly correlated with the TAA ‐specific response. Lastly, the overall survival was significantly prolonged in patients with 2 or more TAA ‐specific CTL responses compared with none to one. Conclusions These results demonstrated several TAA s may be promising for immunotherapy for cholangiocarcinoma, and patients with high lymphocyte counts may benefit more from immunotherapy.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here